|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
EP0425491B1
(en)
|
1988-03-02 |
1994-07-20 |
The Uab Research Foundation |
Reversible mechanochemical engines comprised of bioelastomers capable of modulable inverse temperature transitions for the interconversion of chemical and mechanical work
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
AU2001234128B2
(en)
|
2000-02-22 |
2004-11-11 |
Banyu Pharmaceutical Co., Ltd. |
Novel imidazoline compounds
|
|
KR20020097241A
(ko)
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
JP2002253259A
(ja)
|
2001-03-02 |
2002-09-10 |
Bio Applied Systems:Kk |
抗ビスフェノールａ抗体をコードする遺伝子、組換えタンパク質およびその製造方法
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
EP1432724A4
(en)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
|
|
EP2402753A1
(en)
|
2002-03-11 |
2012-01-04 |
Momenta Pharmaceuticals, Inc. |
Analysis of sulfated polysaccharides
|
|
CA2942791C
(en)
|
2002-11-25 |
2019-08-20 |
Masafumi Matsuo |
Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
|
|
WO2004055164A2
(en)
|
2002-12-13 |
2004-07-01 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
AU2003301020A1
(en)
|
2002-12-20 |
2004-07-22 |
Sankyo Company, Limited |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
WO2005058244A2
(en)
|
2003-12-15 |
2005-06-30 |
Alexion Pharmaceuticals, Inc. |
Novel anti-dc-sign antibodies
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
USRE47769E1
(en)
|
2004-06-28 |
2019-12-17 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
ES2545533T3
(es)
|
2004-11-01 |
2015-09-11 |
The Regents Of The University Of California |
Composiciones y métodos para modificación de biomoléculas
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
WO2006091796A2
(en)
|
2005-02-22 |
2006-08-31 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
EP1991273B2
(en)
|
2006-02-10 |
2022-01-05 |
Life Technologies Corporation |
Labeling and detection of post translationally modified proteins
|
|
US8859752B2
(en)
|
2006-04-18 |
2014-10-14 |
The Trustees Of The University Of Pennsylvania |
SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
MX2009006082A
(es)
|
2006-12-08 |
2009-08-18 |
Lexicon Pharmaceuticals Inc |
Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3).
|
|
TWI595005B
(zh)
|
2007-08-21 |
2017-08-11 |
安健股份有限公司 |
人類ｃ－ｆｍｓ抗原結合蛋白質
|
|
HUE028662T2
(en)
|
2007-10-26 |
2016-12-28 |
Academisch Ziekenhuis Leiden |
Preparations and methods for controlling muscle disorders
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
TR201902952T4
(tr)
|
2008-10-24 |
2019-03-21 |
Sarepta Therapeutics Inc |
Dmd için ekson atlama bileşimleri.
|
|
PT2344637E
(pt)
|
2008-10-27 |
2015-03-23 |
Academisch Ziekenhuis Leiden |
Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
|
|
JP2012524540A
(ja)
|
2009-04-24 |
2012-10-18 |
プロセンサ テクノロジーズ ビー．ブイ． |
Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド
|
|
KR101742334B1
(ko)
|
2009-05-08 |
2017-06-01 |
큐알엔에이, 인크. |
Ｄｍｄ 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
WO2011057350A1
(en)
|
2009-11-12 |
2011-05-19 |
The University Of Western Australia |
Antisense molecules and methods for treating pathologies
|
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
|
WO2011130164A2
(en)
|
2010-04-13 |
2011-10-20 |
The Regents Of The University Of California |
Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
|
|
TWI540136B
(zh)
|
2010-04-15 |
2016-07-01 |
梅迪繆思有限公司 |
吡咯并苯并二氮呯及其共軛物
|
|
DK2563753T6
(en)
|
2010-04-27 |
2016-04-04 |
Synaffix Bv |
Fused cyclooctynforbindelser and their use in metal-free click-reactions
|
|
CA2799501C
(en)
|
2010-05-28 |
2022-02-15 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
PE20130643A1
(es)
|
2010-07-12 |
2013-06-07 |
Covx Technologies Ireland Ltd |
Conjugados de anticuerpos multifuncionales
|
|
AU2011282243B2
(en)
|
2010-07-19 |
2016-09-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of nuclear-retained RNA
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
EP3118316A1
(en)
|
2010-09-02 |
2017-01-18 |
Université de Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
|
DK2646470T3
(en)
|
2010-11-30 |
2017-05-08 |
Hoffmann La Roche |
ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
|
|
EP3296321B1
(en)
|
2010-12-20 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Anti-mesothelin antibodies and immunoconjugates
|
|
JP2014507143A
(ja)
|
2011-02-08 |
2014-03-27 |
ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング／ビジネス／アズ キャロライナズ ヘルスケア システム |
アンチセンスオリゴヌクレオチド
|
|
WO2012138975A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
WO2012178173A1
(en)
|
2011-06-24 |
2012-12-27 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
KR20140048292A
(ko)
|
2011-08-23 |
2014-04-23 |
로슈 글리카트 아게 |
항-mcsp 항체
|
|
US20130066063A1
(en)
|
2011-09-09 |
2013-03-14 |
John Cooke Hodges |
Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
|
|
WO2013085550A2
(en)
|
2011-12-05 |
2013-06-13 |
Duke University |
V1v2 immunogens
|
|
US9725716B2
(en)
|
2011-12-06 |
2017-08-08 |
Ohio State Innovation Foundation and Research Institute at Nationwide Children's Hospital |
Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
|
|
IN2014DN06220A
(enExample)
|
2011-12-28 |
2015-10-23 |
Nippon Shinyaku Co Ltd |
|
|
WO2013103800A1
(en)
|
2012-01-06 |
2013-07-11 |
Bioalliance C.V. |
Anti-transferrin receptor antibodies and methods using same
|
|
US20130323234A1
(en)
|
2012-01-09 |
2013-12-05 |
Covx Technologies Ireland Limited |
Mutant antibodies and conjugation thereof
|
|
CN111893117B
(zh)
|
2012-01-27 |
2024-06-04 |
比奥马林技术公司 |
治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
NZ628804A
(en)
|
2012-02-24 |
2017-08-25 |
Abbvie Stemcentrx Llc |
Dll3 modulators and methods of use
|
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
|
HRP20171254T1
(hr)
|
2012-04-23 |
2018-01-12 |
Biomarin Technologies B.V. |
Oligonukleotidi koji moduliraju rnk s poboljšanim karakteristikama za liječenje neuromišićnih poremećaja
|
|
RU2674600C2
(ru)
|
2012-07-03 |
2018-12-11 |
Просенса Текнолоджиз Б.В. |
Олигонуклеотид для лечения пациентов с мышечной дистрофией
|
|
EP2684892A1
(en)
|
2012-07-13 |
2014-01-15 |
Association Française contre les Myopathies |
Compositions and methods for duchenne muscular dystrophy gene therapy
|
|
CA2880649C
(en)
|
2012-08-01 |
2023-03-14 |
Elizabeth MCNALLY |
Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
CN105142672B
(zh)
|
2012-10-23 |
2019-04-05 |
西纳福克斯股份有限公司 |
经修饰的抗体、抗体-缀合物及其制备方法
|
|
JP6133431B2
(ja)
|
2012-11-24 |
2017-05-24 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
|
|
ME03394B
(me)
|
2013-02-22 |
2020-01-20 |
Medimmune Ltd |
Antidllз-antitelo-pbd konjugati i nihovа upotreba
|
|
SMT201900139T1
(it)
|
2013-03-14 |
2019-05-10 |
Sarepta Therapeutics Inc |
Composizioni di salto dell'esone per il trattamento della distrofia muscolare
|
|
US9217148B2
(en)
|
2013-03-14 |
2015-12-22 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
MX373959B
(es)
|
2013-03-15 |
2020-07-13 |
Sarepta Therapeutics Inc |
Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd).
|
|
HRP20240107T1
(hr)
|
2013-05-20 |
2024-04-12 |
F. Hoffmann - La Roche Ag |
Protutijela na transferinski receptor i postupci uporabe
|
|
EP3004062B1
(en)
|
2013-05-24 |
2017-07-19 |
SynAffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
KR102733409B1
(ko)
|
2013-06-05 |
2024-11-21 |
듀크 유니버시티 |
Rna-가이드 유전자 편집 및 유전자 조절
|
|
BR112016004073A8
(pt)
|
2013-08-28 |
2018-06-12 |
Stemcentrx Inc |
Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3
|
|
AU2014321211A1
(en)
|
2013-09-23 |
2016-05-05 |
President And Fellows Of Harvard College |
Allele-specific RNA silencing for the treatment of hypertrophic cardiomyopathy
|
|
WO2015057065A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
EP3058083B1
(en)
|
2013-10-14 |
2018-04-11 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015073848A1
(en)
|
2013-11-14 |
2015-05-21 |
Shehadeh Lina A |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
EP3097080A1
(en)
|
2014-01-24 |
2016-11-30 |
SynAffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
JP2017505770A
(ja)
|
2014-01-24 |
2017-02-23 |
シンアフィックス ビー．ブイ． |
（ヘテロ）アリール１，３−双極子化合物と（ヘテロ）シクロアルキンとの環化付加のためのプロセス
|
|
AU2015225496A1
(en)
|
2014-03-03 |
2016-10-13 |
Sujata ACHARJEE |
Chimeric dystrophin-VSV-G-protein to treat dystrophinopathies
|
|
EP3514234A1
(en)
|
2014-03-12 |
2019-07-24 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acid
|
|
AR099625A1
(es)
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
CN103882024A
(zh)
|
2014-04-21 |
2014-06-25 |
石河子大学 |
一种RNAi干扰片段、RNAi干扰载体及其应用
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
US20170182189A1
(en)
|
2014-05-23 |
2017-06-29 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
UA121117C2
(uk)
|
2014-06-17 |
2020-04-10 |
Ніппон Шин'Яку Ко., Лтд. |
Антисенсова нуклеїнова кислота
|
|
EP4148138A1
(en)
|
2014-08-04 |
2023-03-15 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
GB201416960D0
(en)
|
2014-09-25 |
2014-11-12 |
Antikor Biopharma Ltd |
Biological materials and uses thereof
|
|
US9714288B2
(en)
|
2014-09-30 |
2017-07-25 |
The Regents Of The University Of California |
Antisense compounds and uses thereof
|
|
CN112494657B
(zh)
|
2014-10-03 |
2025-02-11 |
西纳福克斯股份有限公司 |
磺酰胺接头、其缀合物及制备方法
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
JP6484337B2
(ja)
|
2014-11-21 |
2019-03-13 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
インスリン受容体部分アゴニスト
|
|
ES2659816T3
(es)
|
2015-04-23 |
2018-03-19 |
Synaffix B.V. |
Proceso para la modificación de una glucoproteína utilizando una glucosiltransferasa que es o que deriva de una (1,4)-n-acetilgalactosaminiltransferasa
|
|
LT3292149T
(lt)
|
2015-05-04 |
2022-03-10 |
Cytomx Therapeutics, Inc. |
Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
|
|
MX388743B
(es)
|
2015-05-19 |
2025-03-20 |
Sarepta Therapeutics Inc |
Conjugados oligonucleótido-péptido.
|
|
WO2016205641A2
(en)
|
2015-06-17 |
2016-12-22 |
Research Institute At Nationwide Children's Hospital |
Respiratory syncytial virus having cleavage-resistant g protein and related materials and methods
|
|
MY187033A
(en)
|
2015-06-24 |
2021-08-27 |
Japan Chem Res |
Anti-human transferrin receptor antibody permeating blood-brain barrier
|
|
MX2018000569A
(es)
|
2015-07-22 |
2018-09-27 |
Inatherys |
Anticuerpos anti-tfr y su uso en el tratamiento de trastornos proliferativos e inflamatorios.
|
|
RU2724554C2
(ru)
|
2015-09-15 |
2020-06-23 |
Ниппон Синяку Ко., Лтд. |
Антисмысловая нуклеиновая кислота
|
|
EP3332008A4
(en)
|
2015-09-23 |
2019-01-16 |
Université Laval |
CHANGE OF THE DYSTROPHINE GENE AND USES THEREOF
|
|
BR112018007066A2
(pt)
|
2015-10-09 |
2018-10-23 |
Sarepta Therapeutics Inc |
composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
|
|
JP7511326B2
(ja)
|
2015-10-09 |
2024-07-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物およびその方法
|
|
DK3782639T3
(da)
|
2015-12-08 |
2022-08-29 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
MA44074A
(fr)
|
2015-12-18 |
2018-10-24 |
Eisai R&D Man Co Ltd |
Immunoglobulines conjuguées à la lysine c-terminale
|
|
EP3413922B1
(en)
|
2016-02-08 |
2025-12-10 |
SynAffix B.V. |
Improved sulfamide linkers for use in bioconjugates
|
|
JP7366541B2
(ja)
|
2016-02-19 |
2023-10-23 |
コード バイオセラピューティクス インコーポレイテッド |
核酸キャリア及び治療上の使用方法
|
|
MX2018011542A
(es)
|
2016-03-22 |
2019-02-07 |
Hoffmann La Roche |
Moleculas biespecificas de celulas t activadas por proteasas.
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
|
CN109311920B
(zh)
|
2016-05-24 |
2021-11-09 |
萨勒普塔医疗公司 |
制备磷酸二酰胺吗啉代寡聚物的方法
|
|
EP3463429A4
(en)
|
2016-05-24 |
2020-07-22 |
Merck Sharp & Dohme Corp. |
PARTIAL INSULIN RECEPTOR AGONISTS AND GLP-1 ANALOGUES
|
|
JP2019520339A
(ja)
|
2016-06-03 |
2019-07-18 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド、その組成物および方法
|
|
JP6823269B2
(ja)
|
2016-06-20 |
2021-02-03 |
株式会社ＧｅｎＡｈｅａｄ Ｂｉｏ |
抗体−薬物コンジュゲート
|
|
US20180028554A1
(en)
|
2016-07-05 |
2018-02-01 |
Biomarin Technologies B.V. |
Oligomers Having Bicyclic Scaffold Moeities
|
|
WO2018014042A1
(en)
|
2016-07-15 |
2018-01-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dystrophin transcript
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
CA3043864A1
(en)
|
2016-11-16 |
2018-05-24 |
Biomarin Technologies B.V. |
Substances for targeting various selected organs or tissues
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
EP3545090A1
(en)
|
2016-11-28 |
2019-10-02 |
The Board of Regents of The University of Texas System |
Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
|
|
CA3046220A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
KR20240006023A
(ko)
|
2016-12-19 |
2024-01-12 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
KR102466248B1
(ko)
|
2016-12-26 |
2022-11-10 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
KR20190104381A
(ko)
|
2017-01-06 |
2019-09-09 |
어비디티 바이오사이언시스 엘엘씨 |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
CA3049791A1
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
MA50546A
(fr)
|
2017-06-07 |
2020-09-16 |
Regeneron Pharma |
Compositions et méthodes pour l'internalisation d'enzymes
|
|
US20200155702A1
(en)
|
2017-06-16 |
2020-05-21 |
Eli Lilly And Company |
Engineered Antibody Compounds and Conjuates Thereof
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
KR20250065737A
(ko)
|
2017-09-22 |
2025-05-13 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
US20210145852A1
(en)
|
2017-09-28 |
2021-05-20 |
Sarepta Therapeutics, Inc. |
Combination Therapies for Treating Muscular Dystrophy
|
|
US20200248178A1
(en)
|
2017-09-28 |
2020-08-06 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
MX2020003596A
(es)
|
2017-10-04 |
2020-07-22 |
Avidity Biosciences Inc |
Composiciones de acido nucleico-polipeptido y usos de las mismos.
|
|
JP7394753B2
(ja)
|
2017-10-18 |
2023-12-08 |
サレプタ セラピューティクス， インコーポレイテッド |
アンチセンスオリゴマー化合物
|
|
US20210032622A1
(en)
|
2017-11-09 |
2021-02-04 |
Crispr Therapeutics Ag |
Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
|
|
JP7506601B2
(ja)
|
2017-12-06 |
2024-06-26 |
アビディティー バイオサイエンシーズ，インク． |
筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
|
|
CN108220418B
(zh)
|
2017-12-29 |
2018-11-09 |
东莞博奥木华基因科技有限公司 |
基于多重pcr捕获技术的杜氏/贝氏肌营养不良症的检测试剂盒及方法
|
|
MA51583A
(fr)
|
2018-01-04 |
2020-11-11 |
Avidity Biosciences Inc |
Molécules d'acide nucléique hétéroduplex et leurs utilisations
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
EA202091828A1
(ru)
|
2018-01-31 |
2021-05-24 |
Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем |
Композиции и способы коррекции мутаций дистрофина в кардиомиоцитах человека
|
|
JP2019137675A
(ja)
|
2018-02-05 |
2019-08-22 |
Ｊｃｒファーマ株式会社 |
薬剤を筋肉に送達するための方法
|
|
AU2019218892B2
(en)
|
2018-02-07 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for therapeutic protein delivery
|
|
EP3775203A4
(en)
|
2018-04-12 |
2022-03-30 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2019209764A2
(en)
|
2018-04-26 |
2019-10-31 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers and oligomer conjugates for muscular dystrophy
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
CA3098266A1
(en)
|
2018-05-11 |
2019-11-14 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
AU2019265904A1
(en)
|
2018-05-11 |
2020-11-12 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019241385A2
(en)
|
2018-06-13 |
2019-12-19 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystropy
|
|
US20210261962A1
(en)
|
2018-06-21 |
2021-08-26 |
The Board Of Regents Of The University Of Texas System |
Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy
|
|
SG11202100934PA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
CA3108285A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
SG11202100928QA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US20210324101A1
(en)
|
2018-08-02 |
2021-10-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
|
|
CN112955154A
(zh)
|
2018-08-02 |
2021-06-11 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP3829649A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
ANTI-MUSCLE COMPLEXES AND THEIR USES
|
|
EA202190418A1
(ru)
|
2018-08-02 |
2021-06-23 |
Дайн Терапьютикс, Инк. |
Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
WO2020028840A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP3829635A4
(en)
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF MUSCLE ATROPHY
|
|
US20210322562A1
(en)
|
2018-08-02 |
2021-10-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
CN109306375A
(zh)
|
2018-10-16 |
2019-02-05 |
上海瀚垚生物医学科技有限公司 |
EvaGreen法数字PCR检测DMD拷贝数变异的引物、检测试剂盒及其检测方法
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
WO2020094670A1
(en)
|
2018-11-05 |
2020-05-14 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
SG11202105626TA
(en)
|
2018-12-06 |
2021-06-29 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
WO2020142479A1
(en)
|
2018-12-31 |
2020-07-09 |
Research Institute At Nationwide Children's Hospital |
Dux4 rna silencing using rna targeting crispr-cas13b
|
|
CA3134165A1
(en)
|
2019-03-28 |
2020-10-01 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy with casimersen
|
|
JP7687682B2
(ja)
|
2019-04-08 |
2025-06-03 |
国立大学法人東京科学大学 |
筋疾患治療用医薬組成物
|
|
JP2022528725A
(ja)
|
2019-04-18 |
2022-06-15 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療するための組成物
|
|
AU2020263487A1
(en)
|
2019-04-25 |
2021-12-16 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
CA3142283A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
WO2020247818A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
US20220306685A1
(en)
|
2019-06-07 |
2022-09-29 |
Dyne Therapeutics, Inc. |
Methods of preparing protein-oligonucleotide complexes
|
|
JP2022536495A
(ja)
|
2019-06-19 |
2022-08-17 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療する方法
|
|
US20220288218A1
(en)
|
2019-07-09 |
2022-09-15 |
The Governors Of The University Of Alberta |
Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
|
|
WO2021068761A1
(zh)
|
2019-10-10 |
2021-04-15 |
苏州亲为药业有限公司 |
靶向bcma的具有人猴交叉的人源化单克隆抗体
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
KR20220147575A
(ko)
|
2019-11-27 |
2022-11-03 |
디티엑스 파마, 인크. |
뒤시엔느 근위축증의 치료를 위한 화합물 및 방법
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
WO2021142227A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
JP2023510351A
(ja)
|
2020-01-10 |
2023-03-13 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびそれらの使用
|
|
KR20220125802A
(ko)
|
2020-01-10 |
2022-09-14 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
BR112022013603A2
(pt)
|
2020-01-10 |
2022-09-13 |
Dyne Therapeutics Inc |
Complexos de direcionamento a músculo e usos dos mesmos para tratar distrofia muscular facioescapuloumeral
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
US20230144436A1
(en)
|
2020-01-10 |
2023-05-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20230117883A1
(en)
|
2020-01-24 |
2023-04-20 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
IL295022A
(en)
|
2020-01-31 |
2022-09-01 |
Dyne Therapeutics Inc |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
US20230103793A1
(en)
|
2020-01-31 |
2023-04-06 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
EP4656242A2
(en)
|
2020-03-27 |
2025-12-03 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
WO2021226107A1
(en)
|
2020-05-05 |
2021-11-11 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
BR112023001125A2
(pt)
|
2020-07-23 |
2023-02-14 |
Dyne Therapeutics Inc |
Complexos de direcionamento muscular e usos dos mesmos para tratar distrofinopatias
|
|
CA3186755A1
(en)
|
2020-07-23 |
2022-01-27 |
Romesh R. Subramanian |
Muscle-targeting complexes and uses thereof
|
|
WO2022020109A1
(en)
|
2020-07-23 |
2022-01-27 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
KR20230046297A
(ko)
|
2020-07-23 |
2023-04-05 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
MX2023000958A
(es)
|
2020-07-23 |
2023-04-14 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica.
|
|
IL299667A
(en)
|
2020-07-23 |
2023-03-01 |
Dyne Therapeutics Inc |
Anti-transferrin (TFR) antibody and uses thereof
|
|
KR20230079068A
(ko)
|
2020-09-03 |
2023-06-05 |
다인 세라퓨틱스, 인크. |
단백질-올리고뉴클레오티드 복합체의 제조 방법
|
|
WO2022056266A2
(en)
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
|
|
WO2022120132A1
(en)
|
2020-12-04 |
2022-06-09 |
Dyne Therapeutics, Inc. |
Antibody-oligonucleotide complexes and uses thereof
|
|
EP4271816A4
(en)
|
2020-12-31 |
2025-04-02 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY
|
|
WO2022147207A1
(en)
|
2020-12-31 |
2022-07-07 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
JP2024519601A
(ja)
|
2021-03-31 |
2024-05-20 |
エントラーダ セラピューティクス，インコーポレイティド |
環状細胞透過性ペプチド
|
|
US20250302979A1
(en)
|
2021-04-02 |
2025-10-02 |
Avidity Biosciences, Inc. |
Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping
|
|
WO2022217366A1
(en)
|
2021-04-14 |
2022-10-20 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Modified oligonucleotides for the treatment of duchenne muscular dystrophy
|
|
IL307937A
(en)
|
2021-04-30 |
2023-12-01 |
Sarepta Therapeutics Inc |
Treatment methods for muscular dystrophy
|
|
US20240247259A1
(en)
|
2021-05-10 |
2024-07-25 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
WO2022271549A1
(en)
|
2021-06-21 |
2022-12-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
CN118251238A
(zh)
|
2021-06-21 |
2024-06-25 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途
|
|
TW202307208A
(zh)
|
2021-06-23 |
2023-02-16 |
日商日本新藥股份有限公司 |
反義寡聚物之組合
|
|
CN118591391A
(zh)
|
2021-07-09 |
2024-09-03 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
EP4366741A2
(en)
|
2021-07-09 |
2024-05-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP4366774A4
(en)
|
2021-07-09 |
2025-11-19 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH
|
|
MX2024000489A
(es)
|
2021-07-09 |
2024-04-09 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y formulaciones para el tratamiento de las distrofinopatías.
|
|
JP2024525612A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
US20240318176A1
(en)
|
2021-07-09 |
2024-09-26 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
KR20240035823A
(ko)
|
2021-07-09 |
2024-03-18 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
MX2024000488A
(es)
|
2021-07-09 |
2024-04-09 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de los mismos para tratar la distrofia miotónica.
|
|
EP4389891A4
(en)
|
2021-08-19 |
2025-10-29 |
Univ Nat Corp Tokyo Medical & Dental |
MODIFIED HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
|
|
WO2023026994A1
(ja)
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
|
|
AU2022337260A1
(en)
|
2021-09-01 |
2024-04-04 |
Entrada Therapeutics, Inc. |
Compositions and methods for skipping exon 45 in duchenne muscular dystrophy
|
|
IL311507A
(en)
|
2021-09-16 |
2024-05-01 |
Dyne Therapeutics Inc |
Dosing of muscle targeting complexes for the treatment of dystrophinopathy
|
|
AU2022377070A1
(en)
|
2021-11-01 |
2024-04-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating dystrophinopathies
|
|
EP4429711A1
(en)
|
2021-11-12 |
2024-09-18 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
|
|
IL313728A
(en)
|
2021-12-22 |
2024-08-01 |
Sapreme Tech Bv |
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
|
|
CN118434449A
(zh)
|
2021-12-22 |
2024-08-02 |
萨普雷米科技有限公司 |
包含用于治疗肌肉消耗障碍的治疗性核酸和靶向皂苷的组合物
|
|
EP4452281A1
(en)
|
2021-12-22 |
2024-10-30 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
|
|
CN119137274A
(zh)
|
2022-01-27 |
2024-12-13 |
阿尔伯塔大学理事会 |
用于治疗疾病的调控前体mRNA剪接的肽缀合的反义治疗剂
|
|
WO2023154807A2
(en)
|
2022-02-09 |
2023-08-17 |
Locanabio, Inc. |
Compositions and methods for modulating pre-mrna splicing
|
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
US20250195667A1
(en)
|
2022-03-17 |
2025-06-19 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
CN119343373A
(zh)
|
2022-04-15 |
2025-01-21 |
达因疗法公司 |
用于治疗强直性肌营养不良的肌肉靶向复合物的给药
|
|
CA3255934A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETTING COMPLEXES AND FORMULATIONS FOR THE TREATMENT OF MYOTONIC DYSTROPHY
|
|
KR20250004769A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 그의 용도
|
|
WO2023201318A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
AU2023303022A1
(en)
|
2022-07-06 |
2025-01-02 |
Dyne Therapeutics, Inc. |
Cns targeting complexes and uses thereof
|
|
KR20250034419A
(ko)
|
2022-07-06 |
2025-03-11 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
WO2024064237A2
(en)
|
2022-09-21 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Dmd antisense oligonucleotide-mediated exon skipping efficiency
|
|
AU2023372377A1
(en)
|
2022-10-31 |
2025-05-08 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for skipping exon 45 of a dmd gene
|
|
JP2025538552A
(ja)
|
2022-11-21 |
2025-11-28 |
ペプゲン インコーポレイテッド． |
細胞透過性ペプチド、その複合体、及びそれらの使用方法
|
|
KR20250134232A
(ko)
|
2023-01-10 |
2025-09-10 |
오스퍼바이오 테라퓨틱스 인크. |
사용하기 위한 변형된 다중-세그먼트화 안티센스 올리고뉴클레오티드
|
|
IL322946A
(en)
|
2023-02-27 |
2025-10-01 |
Dyne Therapeutics Inc |
Methods and compositions for inhibiting the progression of intramuscular fibrosis
|
|
WO2025076486A1
(en)
|
2023-10-06 |
2025-04-10 |
Dyne Therapeutics, Inc. |
Biomarkers for repeat expansion diseases
|
|
WO2025147541A1
(en)
|
2024-01-02 |
2025-07-10 |
Dyne Therapeutics, Inc. |
Methods and compositions for treating myotonic dystrophy
|